We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+13.6%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$300M
AUM Growth
-$135K
Cap. Flow
-$18M
Cap. Flow %
-6.01%
Top 10 Hldgs %
82.64%
Holding
32
New
9
Increased
4
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$18.7M
2
ATYR
aTyr Pharma
ATYR
+$18.6M
3
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$17.5M
4
COLL icon
Collegium Pharmaceutical
COLL
+$8.04M
5
ARRY
Array Biopharma Inc
ARRY
+$2.95M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$24.9M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$18M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$14.4M
4
SAGE
Sage Therapeutics
SAGE
+$5.65M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 85.8%
2 Miscellaneous 14.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
1
Atara Biotherapeutics
ATRA
$92.3M
$56.1M 18.7%
42,528
– –
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$40.5M 13.49%
1,685,800
+105,400
+7% +$2.03M
ASMB icon
3
Assembly Biosciences
ASMB
$694M
$30.3M 10.11%
131,176
– –
KYNB
4
Kyntra Bio
KYNB
$32.5M
$28.3M 9.44%
48,216
+32,216
+201% +$18.7M
KITE
5
DELISTED
Kite Pharma, Inc.
KITE
$17.2M 5.72%
281,400
– –
DCOY
6
Decoy Therapeutics
DCOY
$1.9M
$15.6M 5.21%
1
– –
ATYR
7
aTyr Pharma
ATYR
$53M
$15.5M 5.17%
+59,776
New +$18.6M
TVTX icon
8
Travere Therapeutics
TVTX
$6.19B
$11.3M 3.78%
341,650
-68,350
-17% -$1.87M
KIN
9
DELISTED
Kindred Biosciences, Inc.
KIN
$8.83M 2.94%
1,294,431
– –
COLL icon
10
Collegium Pharmaceutical
COLL
$786M
$8.3M 2.77%
+465,118
New +$8.04M
ARRY
11
CALL
DELISTED
Array Biopharma Inc
ARRY
$7.93M 2.64%
11,000
+3,650
+50% +$26.9K
TPST icon
12
CALL
Tempest Therapeutics
TPST
$17.5M
$6.65M 2.22%
+1
New +$91.6K
FWP
13
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$6.05M 2.02%
22,712
– –
GNVC
14
DELISTED
GenVec, Inc.
GNVC
$4.05M 1.35%
198,641
– –
EIGR
15
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.58M 1.19%
+6,318
New +$17.5M
CALA
16
DELISTED
Calithera Biosciences, Inc
CALA
$2.97M 0.99%
20,774
+6,000
+41% +$1.39M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$2.88M 0.96%
+400,000
New +$2.95M
BITI
18
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$2M 0.67%
+100,000
New +$2.09M
GYRE icon
19
Gyre Therapeutics
GYRE
$699M
$1.73M 0.58%
787
– –
MCRB icon
20
Seres Therapeutics
MCRB
$51.3M
$1.66M 0.55%
+2,000
New +$1.75M
QLTI
21
DELISTED
QLT Inc
QLTI
$1.65M 0.55%
+400,000
New +$1.54M
RGLS
22
CALL
DELISTED
Regulus Therapeutics
RGLS
$1.4M 0.47%
+11
New +$17.8K
XENE icon
23
Xenon Pharmaceuticals
XENE
$5.81B
$842K 0.28%
73,000
-147,570
-67% -$2.04M
EPZM
24
CALL
DELISTED
Epizyme, Inc
EPZM
$360K 0.12%
150
– –
IRWD icon
25
CALL
Ironwood Pharmaceuticals
IRWD
$682M
– –
-5,970
Closed -$8M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2015 Portfolio in Review

As of Q2 2015, EcoR1 Capital held 32 positions worth $300M, down 0.04% from $300M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

EcoR1 Capital withdrew a net $18M in Q2 2015, closing 7 positions and reducing 2 holdings. Its most notable exit was RECEPTOS INC COM STK (DE), an estimated $24.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 74% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in aTyr Pharma worth $15.5M.

  • EcoR1 Capital's largest Q2 2015 buy was aTyr Pharma: 59,776 shares worth $15.5M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2015, an estimated $18.7M increase.
  • EcoR1 Capital's biggest Q2 2015 reduction was Xenon Pharmaceuticals, cutting an estimated $2.04M.
  • EcoR1 Capital fully exited RECEPTOS INC COM STK (DE) in Q2 2015, selling an estimated $24.9M.
  • EcoR1 Capital's ten largest holdings make up 83% of its $300M portfolio in Q2 2015.
  • EcoR1 Capital opened 9 new positions and closed 7 in Q2 2015.
  • EcoR1 Capital's portfolio value fell 0.04% quarter-over-quarter to $300M.

Based on EcoR1 Capital's 13F filing for Q2 2015, filed 14 Aug 2015.